[go: up one dir, main page]

AR004400A1 - Un acido nucleico aislado que codifica un polipeptido comprendiendo por lo menos una de las actividades de la osteoprotegerina (opc), polipeptidos,derivados de dichos polipeptidos, multimeros, vectores, celulas huesped, procedimiento para producir la osteoprotegerina, anticuerpos, metodos de deteccion, composiciones farmaceuticas y usos - Google Patents

Un acido nucleico aislado que codifica un polipeptido comprendiendo por lo menos una de las actividades de la osteoprotegerina (opc), polipeptidos,derivados de dichos polipeptidos, multimeros, vectores, celulas huesped, procedimiento para producir la osteoprotegerina, anticuerpos, metodos de deteccion, composiciones farmaceuticas y usos

Info

Publication number
AR004400A1
AR004400A1 ARP960105797A ARP960105797A AR004400A1 AR 004400 A1 AR004400 A1 AR 004400A1 AR P960105797 A ARP960105797 A AR P960105797A AR P960105797 A ARP960105797 A AR P960105797A AR 004400 A1 AR004400 A1 AR 004400A1
Authority
AR
Argentina
Prior art keywords
opg
nucleic acids
seq
polypeptides
activities
Prior art date
Application number
ARP960105797A
Other languages
English (en)
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/577,788 external-priority patent/US6613544B1/en
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AR004400A1 publication Critical patent/AR004400A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)

Abstract

El invento proporciona ácidos nucleicos que codifican un polipéptido teniendo por lo menos una de las actividades biológicas dela OPG. También seproporcionan los ácidos nucleicos que se hibridizan en ácidos nucleicos codificando laOPG de ratones, ratas o humanos tales como se muestran en lasfiguras 2B-2C (SEC.ID. N° 120), 9A-9B (SEC.ID. N° 122) y 9C-9D (SEC.ID. N°124). Preferentemente la OPG es una OPG de mamíferos y más preferentemente una OPGhumana. También se abarcan losvecto res recombinantes y las células huéspedes que expresan la OPG y los métodos para producir la OPG recombinante. También sedescriben los anticuerpos o fragmentos de los mismos que enlazan específicamente los polipéptidos. Lospolipépti dos son útiles para lapreparación de medicamentos para prevenir la resorción de los huesos y pueden utilizarse en el tratamiento de toda condición que sea resultado de pérdida dela masa ósea, tal como la osteoporosis, hipercalcemia, laenfermedad P aget de los huesos y pérdida ósea provocada por la artritis reumatoidea u osteomielitisy similares. Las enfermedades de los huesos pueden tratarse también con terapia antisenso o de genes utilizando los ácidos nucleicos de lainvención.Tamb ién están abarcadas las composiciones farmacéuticas comprendiendo los ácidos nucleicos y polipéptidos de OPG.
ARP960105797A 1995-12-22 1996-12-19 Un acido nucleico aislado que codifica un polipeptido comprendiendo por lo menos una de las actividades de la osteoprotegerina (opc), polipeptidos,derivados de dichos polipeptidos, multimeros, vectores, celulas huesped, procedimiento para producir la osteoprotegerina, anticuerpos, metodos de deteccion, composiciones farmaceuticas y usos AR004400A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/577,788 US6613544B1 (en) 1995-12-22 1995-12-22 Osteoprotegerin
US08/706,945 US6369027B1 (en) 1995-12-22 1996-09-03 Osteoprotegerin

Publications (1)

Publication Number Publication Date
AR004400A1 true AR004400A1 (es) 1998-11-04

Family

ID=27077338

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960105797A AR004400A1 (es) 1995-12-22 1996-12-19 Un acido nucleico aislado que codifica un polipeptido comprendiendo por lo menos una de las actividades de la osteoprotegerina (opc), polipeptidos,derivados de dichos polipeptidos, multimeros, vectores, celulas huesped, procedimiento para producir la osteoprotegerina, anticuerpos, metodos de deteccion, composiciones farmaceuticas y usos

Country Status (31)

Country Link
US (1) US6369027B1 (es)
EP (4) EP0870023A1 (es)
JP (1) JP4657388B2 (es)
KR (1) KR100463584B1 (es)
CN (1) CN1318588C (es)
AR (1) AR004400A1 (es)
AT (1) ATE409745T1 (es)
AU (1) AU710587B2 (es)
BG (1) BG63347B1 (es)
CA (1) CA2210467C (es)
CZ (1) CZ292587B6 (es)
DE (1) DE19654610A1 (es)
DK (1) DK0784093T3 (es)
EE (1) EE04643B1 (es)
ES (1) ES2316152T3 (es)
FR (1) FR2742767B1 (es)
GB (1) GB2312899B (es)
HK (1) HK1001526A1 (es)
HU (1) HU227482B1 (es)
IL (1) IL121520A (es)
MX (1) MX9706193A (es)
NO (1) NO973699L (es)
NZ (2) NZ332915A (es)
PL (1) PL187408B1 (es)
PT (1) PT784093E (es)
RO (1) RO121386B1 (es)
SI (1) SI0784093T1 (es)
SK (1) SK110797A3 (es)
TR (1) TR199601036A2 (es)
WO (1) WO1997023614A1 (es)
YU (1) YU69196A (es)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6919434B1 (en) 1995-02-20 2005-07-19 Sankyo Co., Ltd. Monoclonal antibodies that bind OCIF
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US7078493B1 (en) 1995-03-15 2006-07-18 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like genes
US7632922B1 (en) * 1995-12-22 2009-12-15 Amgen, Inc. Osteoprotegerin
US7005413B1 (en) 1995-12-22 2006-02-28 Amgen Inc. Combination therapy for conditions leading to bone loss
JPH1057071A (ja) * 1996-08-19 1998-03-03 Snow Brand Milk Prod Co Ltd 新規ｄｎａ及びそれを用いた蛋白質の製造方法
EP2002846B1 (en) 1996-12-06 2017-01-25 Amgen Inc. Combination therapy using an IL-1 inhibitor for treating IL-1 mediated diseases
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
DE122010000048I1 (de) * 1996-12-23 2011-05-05 Immunex Corp Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
EP1657255B1 (en) * 1997-04-15 2014-07-30 Sankyo Company, Limited Novel protein and method for producing the protein
CN1264427A (zh) 1997-04-16 2000-08-23 安姆根有限公司 osteoprotegerin结合蛋白和受体
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
AU7469998A (en) * 1997-05-01 1998-11-24 Amgen, Inc. Chimeric opg polypeptides
AU9013998A (en) * 1997-07-21 1999-02-10 Zymogenetics Inc. Tumor necrosis factor receptor ztnfr-5
CA2299619A1 (en) * 1997-08-06 1999-02-18 Regeneron Pharmaceuticals, Inc. Human orphan receptor ntr-1
US6346388B1 (en) 1997-08-13 2002-02-12 Smithkline Beecham Corporation Method of identifying agonist and antagonists for tumor necrosis related receptors TR1 and TR2
WO1999011790A1 (en) * 1997-09-04 1999-03-11 Zymogenetics, Inc. Tumor necrosis factor receptor ztnfr-6
DE69839401T2 (de) * 1997-09-18 2009-05-07 Genentech Inc., San Francisco Dcr3 polypeptid, ein tnfr homolog
EP0974671B1 (en) 1997-09-24 2006-05-31 Sankyo Company, Limited Method for diagnosing bone dysbolism
US6087555A (en) * 1997-10-15 2000-07-11 Amgen Inc. Mice lacking expression of osteoprotegerin
JPH11155420A (ja) * 1997-12-02 1999-06-15 Snow Brand Milk Prod Co Ltd トランスジェニック動物
AU1541699A (en) * 1997-12-16 1999-07-05 Incyte Pharmaceuticals, Inc. Human tumor necrosis factor-r2-like proteins
US6077689A (en) 1997-12-24 2000-06-20 Amgen Inc. Enhanced solubility of recombinant proteins
JP2002503464A (ja) * 1998-02-17 2002-02-05 インサイト・ファーマスーティカルズ・インコーポレイテッド ヒト短鎖ｔｎｆ受容体ファミリタンパク質
US6103472A (en) * 1998-02-20 2000-08-15 Amgen Inc. Methods and compositions for identifying novel secreted mammalian polypeptides in yeast
US6150098A (en) * 1998-02-20 2000-11-21 Amgen Inc. Methods for identifying novel secreted mammalian polypeptides
US6790823B1 (en) * 1998-04-23 2004-09-14 Amgen Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
DE69940058D1 (de) 1998-04-23 2009-01-22 Ajinomoto Kk Stoff mit antithrombotischer aktivität und verfahren zur bestimmung von glycokallidin
CA2328140C (en) 1998-05-14 2012-03-13 Immunex Corporation Method of inhibiting osteoclast activity
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
EP1114166B1 (en) * 1998-09-15 2005-03-23 Pharmexa A/S Method for down-regulating osteoprotegerin ligand activity
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
CZ302155B6 (cs) 1998-10-23 2010-11-18 Kirin-Amgen Inc. Sloucenina, která se váže na mpl receptor, zpusob její výroby, farmaceutická kompozice s jejím obsahem, polynukleotid, vektor a hostitelská bunka
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
CN1183961C (zh) * 1998-10-28 2005-01-12 三共株式会社 骨代谢异常症治疗剂
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
WO2000042216A2 (en) * 1999-01-18 2000-07-20 Osteometer Biotech A/S Genetic predisposition to abnormal calcification conditions
US20030007972A1 (en) * 1999-02-24 2003-01-09 Edward Tobinick Cytokine antagonists and other biologics for the treatment of bone metastases
US7259253B2 (en) * 1999-05-14 2007-08-21 Quark Biotech, Inc. Genes associated with mechanical stress, expression products therefrom, and uses thereof
WO2001003719A2 (en) * 1999-07-09 2001-01-18 Amgen Inc. Combination therapy for conditions leading to bone loss
AUPQ167599A0 (en) * 1999-07-19 1999-08-12 St. Vincent's Institute Of Medical Research Inhibitor of osteoclast precursor formation
IL130989A0 (en) 1999-07-20 2001-01-28 Compugen Ltd Variants of alternative splicing
US6673771B1 (en) 1999-07-28 2004-01-06 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclast activity
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
AU6946300A (en) * 1999-08-30 2001-03-26 Mayo Foundation For Medical Education And Research Use of dna encoding osteoprotegerin to prevent or inhibit metabolic bone disorders
HUP0104688A3 (en) * 1999-09-03 2004-07-28 Amgen Inc Thousand Oaks Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
US20030144187A1 (en) * 1999-09-03 2003-07-31 Colin R. Dunstan Opg fusion protein compositions and methods
AU2005237128B2 (en) * 1999-09-03 2008-09-11 Amgen Inc. Compositions and Methods for the Prevention or Treatment of Cancer and Bone Loss Associated with Cancer
US6808902B1 (en) * 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
CA2394536A1 (en) * 1999-12-16 2001-06-21 Amgen Inc. Tnfr/opg-like molecules and uses thereof
US20030103978A1 (en) 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
EP1294879B1 (en) 2000-06-28 2008-12-31 Amgen Inc. Thymic stromal lymphopoietin receptor molecules and uses thereof
EP1368464B1 (en) * 2000-09-22 2007-07-04 Immunex Corporation Screening assays for agonists or antagonists of receptor activator of nf-kb
WO2002064782A2 (en) * 2001-02-09 2002-08-22 Maxygen Holdings Ltd. Rank ligand-binding polypeptides
ES2337716T3 (es) 2001-04-03 2010-04-28 Societe Des Produits Nestle S.A. Osteoprotegerina en la leche.
JP2005515159A (ja) * 2001-06-06 2005-05-26 イミュネックス・コーポレーション 癌を治療するためのｒａｎｋアンタゴニストの使用
PT2087908T (pt) 2001-06-26 2018-07-16 Amgen Inc Anticorpos contra opgl
EP1270015A3 (en) * 2001-06-29 2004-02-25 Sankyo Company Limited A complex comprising OCIF and Polysaccharide
KR100427299B1 (ko) * 2001-08-10 2004-04-14 한국생명공학연구원 인체 골 재흡수 억제인자（ｈＯＰＧ）를 생산하는 재조합플라스미드 ｐＧＨＯＰＧ（ＫＣＴＣ １０１９ＢＰ）
US20030049694A1 (en) * 2001-09-10 2003-03-13 Chung-Hsiun Wu Production of fusion proteins and use for identifying binding molecules
US6800462B2 (en) * 2001-09-10 2004-10-05 Abgenomics Corporation Production of recombinant proteins in vivo and use for generating antibodies
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
JP4336467B2 (ja) * 2001-10-15 2009-09-30 株式会社林原生物化学研究所 破骨細胞形成抑制因子の産生を調節し得る物質のスクリーニング方法
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
CA2481074A1 (en) 2002-04-05 2003-10-23 Amgen Inc. Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
US7259143B2 (en) * 2002-09-05 2007-08-21 Wisconsin Alumni Research Foundation Method of extending the dose range of vitamin D compounds
US20080249068A1 (en) * 2002-09-05 2008-10-09 Deluca Hector F Method of Extending the Dose Range of Vitamin D Compounds
US7462700B2 (en) 2002-12-10 2008-12-09 Schering-Plough Animal Health Corporation Canine RANKL and methods for preparing and using the same
TWI293882B (en) 2003-03-24 2008-03-01 Sankyo Co Polymeric modifiers and pharmaceutical compositions
MX2007000216A (es) 2004-07-08 2007-03-15 Amgen Inc Peptidos terapeuticos.
WO2006036834A2 (en) 2004-09-24 2006-04-06 Amgen Inc. MODIFIED Fc MOLECULES
CN102977205A (zh) 2004-12-13 2013-03-20 赛弗隆澳大利亚(Vic)私人有限公司 骨保护素变异蛋白
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
JO3324B1 (ar) 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
CA2687141C (en) 2007-05-22 2014-04-01 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
CA2768965C (en) 2009-08-14 2019-06-04 George N. Pavlakis Use of il-15 to increase thymic output and to treat lymphopenia
CA3138758A1 (en) 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Llc Highly soluble leptins
WO2013052456A1 (en) 2011-10-05 2013-04-11 Nanosys, Inc. Silicon nanostructure active materials for lithium ion batteries and processes, compositions, components, and devices related thereto
EA034861B1 (ru) * 2012-03-31 2020-03-30 Р-Фарм Интернешнл, Ооо (Общество С Ограниченной Ответственностью) Композиция, полученная из остеопротегерина, и способ ее использования
EP3574017A1 (en) 2017-01-27 2019-12-04 Kymab Limited Anti-opg antibodies
JP6550413B2 (ja) * 2017-02-24 2019-07-24 アール−ファーム・インターナショナル・リミテッド・ライアビリティ・カンパニーＲ−Ｐｈａｒｍ Ｉｎｔｅｒｎａｔｉｏｎａｌ， Ｌｌｃ オステオプロテゲリン由来の組成物およびその使用
CN111004318B (zh) * 2019-12-30 2022-03-04 北京博康健基因科技有限公司 rhPTH(1-34)蛋白原液的纯化方法
TW202203964A (zh) 2020-04-17 2022-02-01 小利蘭史丹佛大學董事會 用於生物醫藥調配物之聚合物賦形劑
TW202410920A (zh) 2022-05-23 2024-03-16 小利蘭史丹佛大學董事會 包括聚合物賦形劑之抗體生物醫藥調配物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4710473A (en) 1983-08-10 1987-12-01 Amgen, Inc. DNA plasmids
FR2640537B1 (fr) 1988-12-21 1992-02-21 Levy Guy Installation et procede utilisant l'effet laser, pour la coupe ou la vaporisation de materiaux et tissus divers
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
WO1990014363A1 (en) 1989-05-19 1990-11-29 Amgen Inc. Metalloproteinase inhibitor
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
CA2068389A1 (en) * 1991-05-13 1992-11-14 Masahiko Sato Method for inhibiting bone resorption
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
JP3284481B2 (ja) 1993-08-20 2002-05-20 本田技研工業株式会社 車両用油圧作動式変速機の油圧制御回路
US6268212B1 (en) 1993-10-18 2001-07-31 Amgen Inc. Tissue specific transgene expression
JP3433495B2 (ja) 1993-12-30 2003-08-04 カシオ計算機株式会社 表示制御装置および表示制御方法
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
WO1996028546A1 (en) 1995-03-15 1996-09-19 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
US8615703B2 (en) 2010-06-04 2013-12-24 Micron Technology, Inc. Advanced bitwise operations and apparatus in a multi-level system with nonvolatile memory

Also Published As

Publication number Publication date
KR19980703599A (ko) 1998-12-05
BG101813A (en) 1998-09-30
ATE409745T1 (de) 2008-10-15
CA2210467C (en) 2011-02-08
EP1990415A1 (en) 2008-11-12
MX9706193A (es) 1997-11-29
BG63347B1 (bg) 2001-10-31
PL321938A1 (en) 1998-01-05
CZ292587B6 (cs) 2003-10-15
NO973699L (no) 1997-10-21
JP4657388B2 (ja) 2011-03-23
DK0784093T3 (da) 2008-12-15
EP0870023A1 (en) 1998-10-14
PL187408B1 (pl) 2004-07-30
EE04643B1 (et) 2006-06-15
GB2312899A (en) 1997-11-12
KR100463584B1 (ko) 2005-06-07
DE19654610A1 (de) 1997-06-26
NO973699D0 (no) 1997-08-12
FR2742767B1 (fr) 2001-03-30
CN1182452A (zh) 1998-05-20
SK110797A3 (en) 1999-07-12
AU710587B2 (en) 1999-09-23
GB2312899B (en) 1999-05-05
FR2742767A1 (fr) 1997-06-27
HU227482B1 (en) 2011-07-28
IL121520A (en) 2010-11-30
EP2332974A2 (en) 2011-06-15
HUP9801122A2 (hu) 1998-08-28
JPH11503616A (ja) 1999-03-30
EP0784093A1 (en) 1997-07-16
NZ326579A (en) 1999-01-28
SI0784093T1 (sl) 2009-04-30
PT784093E (pt) 2008-12-17
EP2332974A3 (en) 2012-01-11
WO1997023614A1 (en) 1997-07-03
US6369027B1 (en) 2002-04-09
EE9700164A (et) 1998-02-16
CZ253897A3 (cs) 1999-03-17
NZ332915A (en) 2000-07-28
ES2316152T3 (es) 2009-04-01
AU1468697A (en) 1997-07-17
EP0784093B1 (en) 2008-10-01
HK1001526A1 (en) 1998-06-26
YU69196A (en) 1999-11-22
GB9626618D0 (en) 1997-02-05
TR199601036A3 (es) 1997-07-21
CA2210467A1 (en) 1997-07-03
RO121386B1 (ro) 2007-04-30
CN1318588C (zh) 2007-05-30
TR199601036A2 (tr) 1997-07-21
HUP9801122A3 (en) 2000-09-28

Similar Documents

Publication Publication Date Title
AR004400A1 (es) Un acido nucleico aislado que codifica un polipeptido comprendiendo por lo menos una de las actividades de la osteoprotegerina (opc), polipeptidos,derivados de dichos polipeptidos, multimeros, vectores, celulas huesped, procedimiento para producir la osteoprotegerina, anticuerpos, metodos de deteccion, composiciones farmaceuticas y usos
RU2222545C2 (ru) Генотерапевтические способы введения агонистов аполипопротеина а-i и их применение для лечения дислипидемических нарушений
Patthy Homology of the precursor of pulmonary surfactant-associated protein SP-B with prosaposin and sulfated glycoprotein 1.
EP0399806B1 (en) Fibronectin derivative
CN101370821B (zh) 新型肽及其用途
FR2681786B1 (es)
DiMattia et al. Molecular cloning and characterization of stanniocalcin-related protein
ATE359796T1 (de) Verwendung von 2-alpha-methyl-19-nor-20(s)-1- alpha,25-dihydroxyvitamin als knochenersatz
Amini et al. A diecast mineralization process forms the tough mantis shrimp dactyl club
AU689157B2 (en) Fas ligand, part thereof, and DNA coding for the same
DE69637874D1 (de) C-C CHEMOKIN REZEPTOR 3: CKR-3 ODER Eos-L2
KR970705405A (ko) 사람 케모킨 폴리펩타이드(Human Chemokine Polypeptides)
CA2226973A1 (en) Modulators of the function of fas receptors and other proteins
MXPA03000406A (es) Uso de 2-metilen-19-nor-20(s)-1 alfa,25-dihidroxivitamina d3 para incrementar la resistencia de los huesos.
ATE246247T1 (de) Varianten des humanen rekombinanten interferon- gamma (rhu-ifn-gamma) mit erhöhter thermischer stabilität
HUT52551A (en) Process for production of neutrophil-activizating factor
Shin et al. Molecular characterization and expression analysis of stanniocalcin-1 in turbot (Scophthalmus maximus)
EP1272514A4 (en) DNA ENCODING THE HUMAN RECEPTOR OF VANILLOIDE VR3
Mochizuki et al. Molecular cloning and expression of human neurochondrin-1 and-2
Feng et al. A novel human parathyroid hormone (1-34) analog for the treatment of osteoporosis
Harlow et al. Synonymous nucleotide substitution rates of β-tubulin and histone genes conform to high overall genomic rates in rodents but not in sea urchins
DE69920216D1 (de) Biologisches material zur herstellung pharmazeutischer zusammensetzungen zur behandlung von säugetieren
BR9408077A (pt) Enzimas de conversão de endotelina seqências de dna, processos para a obtenção por técnicas genéticas, de enzimas de conversão de endotelina substâncias inhibidoras para enzimas de conversão de endotelina e para a prepação de medicamentos que inibem uma enzima de conversão de endotelina e aplicações da enzima de conversão de endotelina das substâncias inibidoras de anticorpos de uma sequência de dna e de sequências parciais
WO1998054209A3 (en) Human mast cell function-associated antigen (mafa) and uses thereof
JP2000229880A (ja) 骨形成促進剤

Legal Events

Date Code Title Description
FB Suspension of granting procedure